Navigation Links
Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Reports on Recent Status Conference in Federal Actos Bladder Cancer Litigation

New York, NY (PRWEB) June 20, 2013

Actos lawsuit claims involving bladder cancer allegations continue to move forward in the multidistrict litigation now underway in U.S. District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. According to court documents, a Status Conference was held in the Actos bladder cancer litigation on June 20th, at which time the Court received an update on the status of discovery and bellwether trials. The Court also scheduled the litigation’s next Status Conference for July 25th, 2013. (In re: Actos Product Liability Litigation, MDL No. 2299)

“Our Firm continues to hear from patients who may have developed bladder cancer due to long term use of this medication. We are pleased to see Actos lawsuits are progressing, and look forward to the first federal trial next year,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos bladder cancer lawsuit evaluations to patients who developed bladder cancer after using the medication for an extended period of time.

Actos Bladder Cancer Lawsuits
Court documents indicate that more than 1,500 Actos lawsuits have been filed in the Western District of Louisiana. reported on May 1st that hundreds of similar claims have also been filed in state courts in California and Illinois. All of the pending lawsuits allege that long-term use of Actos, a type 2 diabetes drug manufactured by Takeda Pharmaceuticals, may cause or worsen bladder cancer. Plaintiffs further allege that Takeda failed to provide adequate warnings to doctors and patients regarding the drug’s association with an increased risk of bladder cancer.*

According to court records, the first trial in the federal Actos litigation is scheduled to begin on January 27, 2014. In April, the nation’s first trial involving Actos bladder cancer allegations ended with a Los Angeles Superior Court jury awarding $6.5 million to a plaintiff who was diagnosed with the disease after taking Actos for four years. However, the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

Actos lawsuits have been mounting in state and federal courts since June 2011, when the U.S. Food & Drug Administration warned that use of Actos for one year or more had been linked to the development of bladder cancer.** According to, Actos was also pulled from the market in Germany and France that month because of its association with bladder cancer.***

Alleged victims of Actos bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.

*, Bloomberg, May 1, 2013
**, FDA, June 15, 2011
***, Bloomberg, March 5, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.


Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
2. Victim’s Rights to Recover for Actos Bladder Cancer Could Expire Soon
3. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
4. Researchers Offer Explanation for Actos Bladder Cancer Risk
5. New Lawsuit alleges Actos caused Bladder Cancer
6. US Drug Watchdog Now Urges Family Members Of A Diabetic Who Died From Bladder Cancer After Using The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
7. US Drug Watchdog Now Urges Users Of The Diabetes Drug Called Actos To Call The Johnson Law Group if They Have Developed Bladder Cancer-Time Is Of The Essence
8. US Drug Watchdog Now Urges Any US Citizen Who Used the Diabetes Drug Called Actos and Then Developed Bladder Cancer To Contact The Johnson Law Group For A Legal Review
9. US Drug Watchdog Now Urges Loved Ones Of A Diabetic Who Died From Bladder Cancer Who Had Used The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
10. US Drug Watchdog Now Expands Their Efforts to Educate Diabetics About the Diabetes Drug Actos and Bladder Cancer, with the Suggestion Victims Call the Johnson Law Group
11. US Drug Watchdog Now Urges Any Diabetic Who Used the Diabetes Drug Actos and Now Have Been Diagnosed with Bladder Cancer to Call The Johnson Law Group-ASAP
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and ... diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians can ... from their electronic medical record (EMR) without the need for redundant patient entry ...
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
(Date:11/26/2015)... , ... November 26, 2015 , ... PRMA Plastic Surgery ... 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What ... up every day excited to rebuild lives and it’s an honor to have served ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ... These classically-influenced trailer titles work with any font, giving users limitless opportunities to ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... Ein neuer Kombinationsansatz vereint ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... Clinical Cancer Research vom 6. November ... vom 6. November 2015 berichtet. --> ...
(Date:11/27/2015)... Nov. 26, 2015 ... of the "2016 Global Tumor Marker ... Volume and Sales Segment Forecasts, Innovative Technologies, ... report to their offering. --> ... the "2016 Global Tumor Marker Testing ...
(Date:11/26/2015)... Carolina , 26 november 2015 /PRNewswire/ ... (AAIPharma/CML) kondigt de geplande investering aan van ... van de laboratoria en het mondiale hoofdkantoor ... De uitbreiding zal resulteren in extra kantoorruimte ... voldaan aan de groeiende behoeften van de ...
Breaking Medicine Technology: